Weishengyuan (Xiamen) Biotechnology Co., Ltd.

Primary objective: To compare the differences in the absorption extent and absorption rate of benazepril hydrochlorothiazide tablets (specification: 10 mg/12.5 mg) provided by Weishengyuan (Xiamen) Biotechnology Co., Ltd. and benazepril hydrochlorothiazide tablets (trade name: Lotensin HCT®, specification: 10 mg/12.5 mg) produced by Validus Pharmaceuticals LLC under fasting and postprandial conditions in healthy Chinese population by using a single-center, randomized, open, two-period, self-crossover, single-dose fasting administration design and a single-center, randomized, open, three-period partially repeated, self-crossover, single-dose postprandial administration design, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of benazepril hydrochlorothiazide tablets provided by Weishengyuan (Xiamen) Biotechnology Co., Ltd.